CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands -  June 2, 2021

According to public information, on May 31, the Capital Group Companies, Inc. increased its stake in Harbour BioMed by purchasing over 17 million shares. With the increased shares, the stake held by Capital Group reaches 6.1% correspondingly.

About Capital Group 

Capital Group is a global investment manager, we've helped investors succeed by remaining true to our values and approach. They include a distinctive way of managing money, an emphasis on research, a long-term view and a recognition of the power of relationships. Helping investors succeed has helped us grow. Today, we're one of the world's largest  investment management organizations, managing more than USD 2 trillion.

About Harbour BioMed

 
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

 
The Company’s proprietary antibody technology platforms Harbour Mice^® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE^®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice^® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.  

For more information, please visit www.harbourbiomed.com